Patient blood management: A 68-year-old woman contemplating autologous blood donation before elective surgery

JAMA

Volumn 306, Issue 17, 2011, Pages 1902-1910

  Uhl, Lynne ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

AGED; ANEMIA; ARTICLE; AUTOLOGOUS BLOOD DONATION; BLOOD AUTOTRANSFUSION; BLOOD DONOR; BLOOD SAFETY; BURSECTOMY; CASE REPORT; COST EFFECTIVENESS ANALYSIS; ELECTIVE SURGERY; FEMALE; HEALTH CARE COST; HUMAN; INFORMED CONSENT; JOINT LIMITATION; KNEE ARTHROSCOPY; KNEE DISEASE; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE SWELLING; LABORATORY TEST; PATIENT COUNSELING; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TOTAL KNEE REPLACEMENT;

EID: 80355131279     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1526     Document Type: Article

References (89)

1. Holland PV. Consent for transfusion: is it informed? Transfus Med Rev. 1997;11(4):274-285. (Pubitemid 27478091)
2. Killion DF, Schiff PD, Lipton KS. Informed consent: working toward a meaningful dialogue. Transfusion. 2007;47(4):557-558. (Pubitemid 46449643)
3. World Health Organization. 10 Facts on blood transfusion. June 14, 2009. http://www.who.int/bloodsafety/FactFile2009.pdf. Accessed August 23, 2011.
4. Whitaker B, Schlumpf KS, Schulman J, Green J. Report of the US Department of Health and Human Services: The 2009 National Blood Collection and Utilization Survey Report. Washington, DC: Dept of Health and Human Services; 2011.
5. Elmistekawy EM, Errett L, Fawzy HF. Predictors of packed red cell transfusion after isolated primary coronary artery bypass grafting - the experience of a single cardiac center: a prospective observational study. J Cardiothorac Surg. 2009;4:20.
6. Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am. 2002;84-A(2):216-220.
7. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion. 2007;47(8):1468-1480. (Pubitemid 47101072)
8. Epstein JS, Holmberg JA. Progress in monitoring blood safety. Transfusion. 2010;50(7):1408-1412.
9. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;131(5):708-718. (Pubitemid 46726132)
10. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006;355(13):1303-1305. (Pubitemid 44465458)
11. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007;131(5):702-707. (Pubitemid 46729528)
12. Shander A. The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfus Med Rev. 2005;19(1):66-78. (Pubitemid 40248504)
13. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at 4 hospitals. Transfusion. 2010;50(4):753-765.
14. Goodnough LT, Shander A. Blood management. Arch Pathol Lab Med. 2007;131(5):695-701. (Pubitemid 46726131)
15. Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010;113(2):482-495.
16. The Joint Commission. Patient Blood Management Performance Measures Project. June 27, 2011. http://www.jointcommission.org/patient-blood-management- performance-measures-project. Accessed August 26, 2011.
17. Barr PJ, Donnelly M, Morris K, Parker M, Cardwell C, Bailie KE. The epidemiology of red cell transfusion. Vox Sang. 2010;99(3):239-250.
18. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81(1):2-10. (Pubitemid 29068441)
19. Bern MM, Bierbaum BE, Katz JN, Losina E. Autologous blood donation and subsequent blood use in patients undergoing total knee arthroplasty. Transfus Med. 2006;16(5):313-319. (Pubitemid 44453752)
20. Moskowitz DM, Klein JJ, Shander A, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center. Ann Thorac Surg. 2004;77(2):626-634. (Pubitemid 38186523)
21. Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46(7):1120-1129. (Pubitemid 44139485)
22. Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106(1):13-22.
23. Patel MS, Carson JL. Anemia in the preoperative patient. Med Clin North Am. 2009;93(5):1095-1104.
24. Theusinger OM, Leyvraz PF, Schanz U, Seifert B, Spahn DR. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology. 2007;107(6):923-927. (Pubitemid 350175674)
25. Mahadevan D, Challand C, Keenan J. Revision total hip replacement: predictors of blood loss, transfusion requirements, and length of hospitalisation. J Orthop Traumatol. 2010;11(3):159-165.
26. Myers E, O'Grady P, Dolan AM. The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg. 2004;124(10):699-701. (Pubitemid 40057895)
27. Martinez V, Monsaingeon-Lion A, Cherif K, Judet T, Chauvin M, Fletcher D. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Br J Anaesth. 2007;99(6):794-800. (Pubitemid 351773367)
28. Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized preoperative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009;19(1):35-42.
29. Faris PM, Ritter MA. Epoetin alfa: a bloodless approach for the treatment of perioperative anemia. Clin Orthop Relat Res. 1998;(357):60-67. (Pubitemid 29022433)
30. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96(3):823-833. (Pubitemid 30616842)
31. Laupacis A, Feagan B, Wong C; COPES Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet. 1993;342(8867):378. (Pubitemid 23227593)
32. Faris PM, Ritter MA, Abels RI; American Erythropoietin Study Group. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am. 1996;78(1):62-72. (Pubitemid 26028674)
33. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop (Belle Mead NJ). 1996;25(8):533-542.
34. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of 2 dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop (Belle Mead NJ). 1996;25(8):544-552.
35. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood. 1997;89(2):411-418. (Pubitemid 27051675)
36. D'Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997;64(6):1686-1693. (Pubitemid 28066539)
37. Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ. A prospective randomized comparison of 3 blood conservation strategies for radical prostatectomy. Anesthesiology. 1999;91(1):24-33. (Pubitemid 29307333)
38. Olijhoek G, Megens JG, Musto P, et al. Role of oral vs IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion. 2001;41(7):957-963. (Pubitemid 32642770)
39. Moonen AF, Thomassen BJ, Knoors NT, van Os JJ, Verburg AD, Pilot P. Preoperative injections of epoetin-alpha vs postoperative retransfusion of autologous shed blood in total hip and knee replacement: a prospective randomised clinical trial. J Bone Joint Surg Br. 2008;90(8):1079-1083.
40. Karkouti K, McCluskey SA, Evans L, Mahomed N, Ghannam M, Davey R. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anaesth. 2005;52(4):362-368. (Pubitemid 40753820)
41. Wong CJ, Vandervoort MK, Vandervoort SL, et al. A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty. Transfusion. 2007;47(5):832-841. (Pubitemid 46668997)
42. Jabbour N, ed. Preoperative management and preparation for transfusion-free surgery. InTransfusion-Free Medicine and Surgery. Oxford, England: Blackwell; 2005:60-74.
43. Fergusson DA, Hébert P. The health(y) cost of erythropoietin in orthopedic surgery. Can J Anaesth. 2005;52(4):347-351. (Pubitemid 40753817)
44. Vitale MG, Roye BD, Ruchelsman DE, Roye DP Jr. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for longterm outcomes. Spine J. 2007;7(3):292-300. (Pubitemid 46679514)
45. Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donation in reducing allogeneic blood transfusions in coronary artery bypass graft surgery. Transfusion. 2000;40(6):673-681. (Pubitemid 30413320)
46. Goodnough LT. Autologous blood donation. Crit Care. 2004;8(suppl 2):S49-S52. (Pubitemid 39144732)
47. Goodnough LT, Saha P, Hirschler NV, Yomtovian R. Autologous blood donation in nonorthopaedic surgical procedures as a blood conservation strategy. Vox Sang. 1992;63(2):96-101.
48. Stowell CP, Chandler H, Jové M, Guilfoyle M, Wacholtz MC. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics. 1999;22(1)(suppl):s105-s112. (Pubitemid 29045415)
49. Keating EM, Callaghan JJ, Ranawat AS, Bhirangi K, Ranawat CS. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty. 2007;22(3):325-333. (Pubitemid 46505220)
50. Yazer M, Triulzi D. Messages from national blood data collection reports. Transfusion. 2007;47(3):366-368.
51. Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion. 2001;41(12):1459-1462. (Pubitemid 34072665)
52. Henry DA, Carless PA, Moxey AJ, O'Connell D, Ker K, Fergusson DA. Preoperative autologous donation for minimising perioperative allogeneic blood transfusion. April 14, 2010. http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD003602/abstract;jsessionid=1F4C582076EE3DAD19BF1F98BE5DE886.d02t04. Accessed October 12, 2011.
53. Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am. 2002;84-A(8):1299-1304. (Pubitemid 35407572)
54. McVay PA, Andrews A, Kaplan EB, et al. Donation reactions among autologous donors. Transfusion. 1990;30(3):249-252. (Pubitemid 20112730)
55. Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion. 2003;43(5):598-603. (Pubitemid 36506355)
56. Newman B, Tommolino E, Andreozzi C, Joychan S, Pocedic J, Heringhausen J. The effect of a 473-mL (16-oz) water drink on vasovagal donor reaction rates in high-school students. Transfusion. 2007;47(8):1524-1533. (Pubitemid 47101079)
57. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332(11):719-724.
58. Goodnough LM, Grishaber JE, Birkmeyer JD, Monk TG, Catalona WJ. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology. 1994;44(2):226-231.
59. Birkmeyer JD, AuBuchon JP, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg. 1994;57(1):161-168.
60. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion. 1993;33(7):544-551. (Pubitemid 23210789)
61. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual Chapter 15 - Covered Medical and Other Health Services. July 8, 2011. http://www.cms.gov/manuals/Downloads/bp20102c15.pdf. Accessed October 11, 2011.
62. Centers forMedicare and Medicaid Services. Medicare National Coverage Determinations Manual: Chapter 1, Part 2 (Sections 90-160.26): Coverage Determinations. July 8, 2011. http://www.cms.gov/manuals/downloads/ncd103c1- Part2.pdf. Accessed October 11, 2011.
63. Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion. 2004;44(5):632-644. (Pubitemid 38608238)
64. Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia. Br J Anaesth. 2010;105(4):401-416.
65. Waters JH. Indications and contraindications of cell salvage. Transfusion. 2004;44(12)(suppl):40S-44S. (Pubitemid 39636418)
66. Freischlag JA. Intraoperative blood salvage in vascular surgery - worth the effort? Crit Care. 2004;8(suppl 2):S53-S56. (Pubitemid 39144733)
67. Stehling L, ed. Guidelines for Establishing an Autologous Program - Pitfalls and How to Avoid Them. Arlington, VA: AABB Press; 1991.
68. Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010;4(4):CD001888.
69. Domen RE. Adverse reactions associated with autologous blood transfusion: evaluation and incidence at a large academic hospital. Transfusion. 1998;38(3):296-300. (Pubitemid 28180650)
70. Shander AS, Goodnough LT. Blood transfusion as a quality indicator in cardiac surgery. JAMA. 2010;304(14):1610-1611.
71. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559-1567.
72. Ferraris VA, Ferraris SP, Saha SP, et al. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5)(suppl):S27-S86. (Pubitemid 46621124)
73. Seifried E, Klueter H, Weidmann C, et al. How much blood is needed? Vox Sang. 2011;100(1):10-21.
74. Hébert PC, Wells G, Blajchman MA, et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340(6):409-417. (Pubitemid 29084771)
75. Rhamy JF. Synergies between blood center and hospital quality systems. Transfusion. 2010;50(12 pt 2):2793-2797.
76. Department of Health and Human Services. Biovigilance in the United States: Efforts to Bridge a Critical Gap in Patient Safety and Donor Health. 2009. http://www.hhs.gov/ash/bloodsafety/biovigilance/ash-to-acbsa-oct-2009.pdf. Accessed August 26, 2011.
77. Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood. 2011;117(5):1463-1471.
78. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusionrelated acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion. 2010;50(8):1732-1742.
79. Stainsby D, Jones H, Asher D, et al. SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20(4):273-282. (Pubitemid 44428107)
80. Glynn SA. The red blood cell storage lesion: a method to the madness. Transfusion. 2010;50(6):1164-1169.
81. Davis RE, Vincent CA, Murphy MF. Blood transfusion safety: the potential role of the patient. Transfus Med Rev. 2011;25(1):12-23.
82. Chambers LA, Kruskall MS. Preoperative autologous blood donation. Transfus Med Rev. 1990;4(1):35-46.
83. Toy P, Hoag MS, Lamberson HV. Higher non-A, non-B hepatitis surrogate marker rates in designated donor units [abstract]. Transfusion. 1988;28(suppl):17S.
84. Davis M, Sofer M, Gomez-Marin O, Bruck D, Soloway MS. The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int. 2003;91(6):474-476. (Pubitemid 36570563)
85. Liang TB, Li DL, Liang L, et al. Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: efficiency of leukocyte depletion filters in the removal of tumor cells. Transplantation. 2008;85(6):863-869. (Pubitemid 351440752)
86. Suitability of donor. 21 CFR §640.3.
87. AABB. Standards for Blood Banks and Transfusion Services. 27th ed. Bethesda, MD: AABB; 2011.
88. Eder AF. Allogeneic and autologous blood donor selection. In: Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds. Technical Manual. 16th ed. Bethesda, MD: AABB; 2008:137-181.
89. Goodnough LT. Alternatives to allogeneic transfusion in patients with surgical anemia. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice. 3rd ed. Bethesda, MD: AABB Press; 2011:699-720.